drugset / Trial / NCT02914470
Carboplatin-cyclophosphamide Combined With Atezolizumab
NaSingle-groupOpen-labelTreatment
Summary
This is a single centre, 3+3, dose finding, open label, phase 1b clinical study of carboplatin and cyclophosphamide, in combination with atezolizumab.
Timeline
- Start
- 2017-01
- Primary completion
- 2017-08
- Completion
- 2021-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 840 mg | — |
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |